Menü
Du musst dich anmelden oder registrieren, bevor du fortfahren kannst.
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

Got $1,000? 2 Bulletproof Stocks to Buy in 2024 and Hold for the Long Haul: https://g.foolcdn.com/editorial/images/771624/dna-sequencing-genome-science-lab.jpg
Got $1,000? 2 Bulletproof Stocks to Buy in 2024 and Hold for the Long Haul

While no one can say with absolute certainty what the market will or won't do in 2024, finding great stocks that have the power to stand the test of time in your portfolio doesn't have to be

Got $1,000? 2 Bulletproof Stocks to Buy in 2024 and Hold for the Long Haul: https://g.foolcdn.com/editorial/images/771624/dna-sequencing-genome-science-lab.jpg
Got $1,000? 2 Bulletproof Stocks to Buy in 2024 and Hold for the Long Haul

While no one can say with absolute certainty what the market will or won't do in 2024, finding great stocks that have the power to stand the test of time in your portfolio doesn't have to be

Why Humana Stock Fell 10.9% This Week: https://g.foolcdn.com/editorial/images/771845/doctor-seeing-elderly-patient.jpg
Why Humana Stock Fell 10.9% This Week

Shares of Humana (NYSE: HUM) are down 11.8% so far this week as of Thursday's close, according to data provided by S&P Global Market Intelligence, after the U.S. Centers for Medicare and Medicaid

Better Booming Biotech Stock: Madrigal Pharmaceuticals vs. Viking Therapeutics: https://g.foolcdn.com/editorial/images/770857/standing-pair-of-investors-consider-tablet-and-computer.jpg
Better Booming Biotech Stock: Madrigal Pharmaceuticals vs. Viking Therapeutics

Madrigal Pharmaceuticals (NASDAQ: MDGL) and Viking Therapeutics (NASDAQ: VKTX) are both biotechs developing treatments for metabolic diseases, so it's to be expected that they have more than a few

Should You Sell This Stock Following a Regulatory Roadblock?: https://g.foolcdn.com/editorial/images/770862/physician-talking-to-patient.jpg
Should You Sell This Stock Following a Regulatory Roadblock?

Biotech giant Regeneron Pharmaceuticals (NASDAQ: REGN) has been on fire over the past three years. The company has delivered solid clinical progress and an important regulatory approval, and its

Should You Sell This Stock Following a Regulatory Roadblock?: https://g.foolcdn.com/editorial/images/770862/physician-talking-to-patient.jpg
Should You Sell This Stock Following a Regulatory Roadblock?

Biotech giant Regeneron Pharmaceuticals (NASDAQ: REGN) has been on fire over the past three years. The company has delivered solid clinical progress and an important regulatory approval, and its

Should You Sell This Stock Following a Regulatory Roadblock?: https://g.foolcdn.com/editorial/images/770862/physician-talking-to-patient.jpg
Should You Sell This Stock Following a Regulatory Roadblock?

Biotech giant Regeneron Pharmaceuticals (NASDAQ: REGN) has been on fire over the past three years. The company has delivered solid clinical progress and an important regulatory approval, and its

Acadia Healthcare Appoints Dr. Stephanie Eken as Chief Medical Officer: https://mms.businesswire.com/media/20240404108920/en/2088322/5/StephanieEken_Acadia1534-Edited.jpg
Acadia Healthcare Appoints Dr. Stephanie Eken as Chief Medical Officer


Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced the appointment of Dr. Stephanie Eken as the Company’s new chief medical officer. Dr. Eken is a psychiatrist with more than two

Viking Therapeutics Just Announced More Positive Results: Time to Buy?: https://g.foolcdn.com/editorial/images/771116/patient-taking-medicine.jpg
Viking Therapeutics Just Announced More Positive Results: Time to Buy?

Are we witnessing the rise of a new biotech giant? A few weeks ago, Viking Therapeutics (NASDAQ: VKTX) grabbed headlines when it reported positive results from a phase 2 clinical trial for VK2735, a

1 Brand-New (Good) Reason to Buy Viking Therapeutics Stock Now: https://g.foolcdn.com/editorial/images/771186/doctor-and-nurse-talk-with-investor.jpg
1 Brand-New (Good) Reason to Buy Viking Therapeutics Stock Now

Viking Therapeutics (NASDAQ: VKTX) is on a tear this year, with shares catapulting upward by 340% thanks to good data (and high expectations) from one of its mid-stage clinical trials testing a

2 Potentially Explosive Stocks to Buy in April: https://g.foolcdn.com/editorial/images/771446/smiling-man-holding-fist-up.jpg
2 Potentially Explosive Stocks to Buy in April

What's the most important ingredient for investing successfully? Time. However, some stocks require much less time to deliver huge returns than others.

You may have to be patient for significant

Could This 1 Detail Help Viking Therapeutics Top Eli Lilly and Novo Nordisk in the Weight Loss Drug Market?: https://g.foolcdn.com/editorial/images/771655/gettyimages-1351333930.jpg
Could This 1 Detail Help Viking Therapeutics Top Eli Lilly and Novo Nordisk in the Weight Loss Drug Market?

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) have seen their revenue soar in recent times thanks to their weight loss drugs. The companies sell products that target key hormones involved in

Why Amarin Stock Was Rocketing Higher on Wednesday: https://g.foolcdn.com/editorial/images/771713/medical-professionals-conferring-in-a-hospial-corridor.jpg
Why Amarin Stock Was Rocketing Higher on Wednesday

Any one-product company that receives good news about that product will likely attract investors. That was the case Wednesday with Amarin (NASDAQ: AMRN), which received very encouraging news about

1 Beaten-Down Stock to Buy and 1 to Avoid Like the Plague: https://g.foolcdn.com/editorial/images/771003/physician-on-a-virtual-consultation-with-patient.jpg
1 Beaten-Down Stock to Buy and 1 to Avoid Like the Plague

Sometimes it is worth it to buy shares of companies on the dip, and sometimes it isn't. It all depends on whether there are good reasons to believe the company in question will bounce back, and if

QuidelOrtho Receives FDA 510(k) Clearance for Its QuickVue® COVID-19 Test: https://mms.businesswire.com/media/20240401748874/en/2086245/5/1542601_QV_UC_COVID-19_2T_Angle01.jpg
QuidelOrtho Receives FDA 510(k) Clearance for Its QuickVue® COVID-19 Test


QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho" or the “Company”) has received U.S. Food and Drug Administration (“FDA”) 510(k) clearance for its QuickVue COVID-19 test. This clearance allows

STAAR Surgical Celebrates Three Million Lens Milestone at ASCRS Meeting, Unveils New EVO ICL Data and Latest Innovation for 2024: https://mms.businesswire.com/media/20240402599401/en/2086323/5/Image_1_STAAR_Will-Levis-Invite_1x1.jpg
STAAR Surgical Celebrates Three Million Lens Milestone at ASCRS Meeting, Unveils New EVO ICL Data and Latest Innovation for 2024


STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL) for myopia, astigmatism and presbyopia, comes to

EQS-AGM: Fresenius SE & Co. KGaA: Announcement  of the Convening of the General Meeting in Frankfurt am Main on 17.05.2024 according to article 121 AktG (German Stock Companies Act) with the objective of Europe-wide distribution: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24693/Fresenius.svg.png
EQS-AGM: Fresenius SE & Co. KGaA: Announcement of the Convening of the General Meeting in Frankfurt am Main on 17.05.2024 according to article 121 AktG (German Stock Companies Act) with the objective of Europe-wide distribution
EQS-AGM: Fresenius SE & Co. KGaA: Announcement of the Convening of the General Meeting in Frankfurt am Main on 17.05.2024 according to article 121 AktG (German Stock Companies Act) with the objective of Europe-wide distribution
Should You Buy This Blue Chip Stock's Dip Hand Over Fist?: https://g.foolcdn.com/editorial/images/770902/medical-technician.jpg
Should You Buy This Blue Chip Stock's Dip Hand Over Fist?

Cyberattacks can disrupt corporations, and you've seen that play out in recent weeks. UnitedHealth Group (NYSE: UNH) fell roughly $14 billion behind in paying claims after a hacker group attacked

Should You Buy This Blue Chip Stock's Dip Hand Over Fist?: https://g.foolcdn.com/editorial/images/770902/medical-technician.jpg
Should You Buy This Blue Chip Stock's Dip Hand Over Fist?

Cyberattacks can disrupt corporations, and you've seen that play out in recent weeks. UnitedHealth Group (NYSE: UNH) fell roughly $14 billion behind in paying claims after a hacker group attacked

Could Viking Therapeutics Stock Be a Millionaire Maker?: https://g.foolcdn.com/editorial/images/771424/scientists-happy.jpg
Could Viking Therapeutics Stock Be a Millionaire Maker?

There aren't many hotter stocks on the market right now than Viking Therapeutics (NASDAQ: VKTX). Shares of the biopharmaceutical company have skyrocketed around 340% so far this year.

However, those

Viking Therapeutics Stock Has 72% Upside, According to 1 Wall Street Analyst: https://g.foolcdn.com/editorial/images/771231/investor-thinking-about-stock-charts-getty.jpg
Viking Therapeutics Stock Has 72% Upside, According to 1 Wall Street Analyst

Investors looking for stocks that can make dramatic gains in a short time frame might want to turn their attention to the biopharmaceutical industry. Shares of Viking Therapeutics (NASDAQ: VKTX)

2 Stocks Down 30% and 27% to Buy and Hold: https://g.foolcdn.com/editorial/images/770988/doctor-vaccinating-a-patient.jpg
2 Stocks Down 30% and 27% to Buy and Hold

No pair of companies dominated the COVID-19 vaccine market quite like Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA). Both saw their revenue and earnings skyrocket, along with their share prices, as

2 Stocks Down 30% and 27% to Buy and Hold: https://g.foolcdn.com/editorial/images/770988/doctor-vaccinating-a-patient.jpg
2 Stocks Down 30% and 27% to Buy and Hold

No pair of companies dominated the COVID-19 vaccine market quite like Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA). Both saw their revenue and earnings skyrocket, along with their share prices, as

Better Recovery Story Buy: Pfizer vs Moderna: https://g.foolcdn.com/editorial/images/771147/gettyimages-1292931102.jpg
Better Recovery Story Buy: Pfizer vs Moderna

A few years ago, both Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA) were flying high: from an earnings and share performance perspective. They each sold a leading coronavirus vaccine -- and Pfizer

Better Recovery Story Buy: Pfizer vs Moderna: https://g.foolcdn.com/editorial/images/771147/gettyimages-1292931102.jpg
Better Recovery Story Buy: Pfizer vs Moderna

A few years ago, both Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA) were flying high: from an earnings and share performance perspective. They each sold a leading coronavirus vaccine -- and Pfizer